The Value Of Plasma MIF Level In Predicting The Clinical Outcome After PCI In Patients With STEMI Complicated With Metabolic Syndrome

Objective:Macrophage migration inhibitory factor(MIF)is a widely expressed pleiotropic cytokine in different cell types that involves several cardiovascular diseases in addition to inflammatory diseases,and its plasma levels are elevated in the early stages of acute myocardial infarction(AMI).Metabolic syndrome(MS),a major risk factor for cardiovascular and cerebrovascular diseases,has a negative impact on the prognosis of patients with acute ST-segment elevation myocardial infarction(STEMI).This study was designed to investigate the association between plasma MIF levels and long-term prognosis in patients with STEMI and MS.Methods:From December 2015 to June 2017,417 patients with STEMI who underwent emergency percutaneous coronary intervention were included in the observation group,including 267 cases(150 cases in the MS group and non-MS group).Coronary angiography showed 137 healthy controls with normal coronary artery as the control group.MIF levels were determined by enzyme-linked immunosorbent assay and compared between groups.Basic clinical data and coronary angiography results after admission were collected.Patients were followed up and major cardiovascular and cerebrovascular adverse events(MACCE events)were reviewed at 3 years of follow-up.Results:(1)Compared with the control group,plasma MIF levels were significantly increased in STEMI patients with or without MS,P < 0.01;(2)There was no statistical data on MIF levels in patients with STEMI combined with MS and plasma MIF levels in non-combined MS patients.Learning differences;(3)MIF levels have a guiding value for predicting long-term cardiovascular events in patients with MS for 3 years,and have no guiding value for long-term prognosis in patients with non-combined MS.Conclusion:(1)The serum MIF content of patients with STEMI was significantly higher than that of the normal control group,and the more severe the coronary lesions,the more obvious the increase;(2)The risk of MACCE events in the MS group was significantly higher than that in the non-MS group.Thus,MIF levels can guide the 3 years long-term prognosis of STEMI patients with MS.